Halozyme Therapeutics, Inc.
HALO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001159036
In the last 90 days, Halozyme Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 674 institutions reported holding it in 13F filings for Q2 2026, worth $9.62B in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Halozyme Therapeutics, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 619
- +27 vs. Q3 2025
- Shares held
- 123.2M
- +4.48M (+3.8%) vs. Q3 2025
- Total value
- $8.29B
- −$418.1M (−4.8%) vs. Q3 2025
- New holders
- 110
- 218 more added
- Sold out
- 83
- 222 more reduced
12 institutions that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting HALO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 674 | $9.62B |
| Q1 2026 | 637 | $7.79B |
| Q4 2025 | 619 | $8.29B |
| Q3 2025 | 604 | $8.75B |
| Q2 2025 | 552 | $6.05B |
| Q1 2025 | 550 | $7.72B |
| Q4 2024 | 509 | $5.86B |
| Q3 2024 | 510 | $7.17B |
| Q2 2024 | 460 | $6.40B |
| Q1 2024 | 413 | $5.03B |
| Q4 2023 | 411 | $4.62B |
| Q3 2023 | 390 | $4.71B |
| Q2 2023 | 370 | $4.45B |
| Q1 2023 | 387 | $4.77B |
| Q4 2022 | 423 | $7.35B |
| Q3 2022 | 357 | $5.21B |
| Q2 2022 | 368 | $5.65B |
| Q1 2022 | 316 | $5.12B |
| Q4 2021 | 326 | $5.21B |
| Q3 2021 | 326 | $5.29B |
| Q2 2021 | 315 | $5.89B |
| Q1 2021 | 337 | $5.53B |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Halozyme Therapeutics, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Clayton Financial Group LLC | 0 | $0 | 0.00% | −17−100.0% | Sold out |
| Cloud Capital Management, LLC | 0 | $0 | 0.00% | −19−100.0% | Sold out |
| Glenmede Investment Management, LP | – | – | – | – | Not filed |
| AXA Investment Managers S.A. | – | – | – | – | Not filed |
| EFG Asset Management (North America) Corp. | – | – | – | – | Not filed |
| Synovus Financial Corp | – | – | – | – | Not filed |
| Wolverine Trading, LLC | – | – | – | – | Not filed |
| Pinebridge Investments, L.P. | – | – | – | – | Not filed |
| Oak Hill Wealth Advisors, LLC | – | – | – | – | Not filed |
| Lindenwold Advisors | – | – | – | – | Not filed |
| Wetherby Asset Management Inc | – | – | – | – | Not filed |
| Shell Asset Management Co | – | – | – | – | Not filed |
| Lingohr & Partner Asset Management GmbH | – | – | – | – | Not filed |
| Hemington Wealth Management | – | – | – | – | Not filed |